Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL–AF4 fusion protein

Proteasome inhibitors bortezomib and carfilzomib are approved for the treatment of multiple myeloma and mantle cell lymphoma and have demonstrated clinical efficacy for the treatment of acute lymphoblastic leukemia (ALL). The t(4;11)(q21;q23) chromosomal translocation that leads to the expression of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, Tyler W., Downey-Kopyscinski, Sondra L., Fields, Jennifer L., Rahme, Gilbert J., Colley, William C., Israel, Mark A., Maksimenko, Andrey V., Fiering, Steven N., Kisselev, Alexei F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149845/
https://www.ncbi.nlm.nih.gov/pubmed/34035431
http://dx.doi.org/10.1038/s41598-021-90451-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149845/
https://www.ncbi.nlm.nih.gov/pubmed/34035431
http://dx.doi.org/10.1038/s41598-021-90451-9

Ejemplares similares